StocksMedium•13 October 2026•
1 min read
Scienture Revenue Jumps 256% in Q3 as Firm Targets 2027 Profitability
Key Facts
1Scienture Holdings reported Q3 revenue of $1.22M, representing a 256% increase quarter-over-quarter.
2The revenue growth was primarily driven by the expansion of Arbli and the market launch of Rezenopy.
3The drugmaker is targeting achieving profitability by the year 2027.
Scienture Holdings reported Q3 revenue of $1.22M, representing a 256% increase quarter-over-quarter. Benzinga reported that the revenue growth was primarily driven by the expansion of Arbli sales and the market launch of Rezenopy. The drugmaker is currently targeting achieving profitability by the year 2027.
SCNX closed at $3.91 on October 12, 2026, with the stock reaching a day high of $3.91 and a low of $3.58. These financial results provide a positive signal for the biotech firm as it continues to scale its primary product lines.